-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Typhella in Typhoid Fever
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Typhella in Typhoid Fever report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Typhella in Typhoid Fever Drug Details: Typhella is under development for the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Salmonella Immunotherapy in Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Salmonella Immunotherapy in Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Salmonella Immunotherapy in Non...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Tislelizumab in Ureter Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Tislelizumab in Ureter Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Tislelizumab in Ureter Cancer Drug Details: Tislelizumab (Baizean, Tevimbra) is a...
-
Product Insights
Plague – Drugs In Development, 2023
Global Markets Direct’s, ‘Plague - Drugs In Development, 2023’, provides an overview of the Plague pipeline landscape. The report provides comprehensive information on the therapeutics under development for Plague, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key...
-
Product Insights
Traveler’s Diarrhea – Drugs In Development, 2023
Global Markets Direct’s, ‘Traveler's Diarrhea - Drugs In Development, 2023’, provides an overview of the Traveler's Diarrhea pipeline landscape. The report provides comprehensive information on the therapeutics under development for Traveler's Diarrhea, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Typhoid Fever – Drugs In Development, 2023
Global Markets Direct’s, ‘Typhoid Fever - Drugs In Development, 2023’, provides an overview of the Typhoid Fever pipeline landscape. The report provides comprehensive information on the therapeutics under development for Typhoid Fever, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Diarrhea – Drugs In Development, 2023
Global Markets Direct’s, ‘Diarrhea - Drugs In Development, 2023’, provides an overview of the Diarrhea pipeline landscape. The report provides comprehensive information on the therapeutics under development for Diarrhea, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key...
-
Product Insights
Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) – Drugs In Development, 2023
Global Markets Direct’s, ‘Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) - Drugs In Development, 2023’, provides an overview of the Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Salmonella Immunotherapy in Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer)
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Salmonella Immunotherapy in Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) Drug Details: The...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – KSP-1007 in Bacterial Infections
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. KSP-1007 in Bacterial Infections Drug Details: KSP-1007 is under development for the treatment of...